Social Determinants of Health Research Center, Birjand University of Medical Sciences, Birjand, Iran
Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
BMJ Open. 2020 Jul 31;10(7):e039730. doi: 10.1136/bmjopen-2020-039730.
An outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was reported in Wuhan, China, in mid-December 2019, and declared a pandemic by the WHO on 11 March 2020. Due to the unknown nature of the disease and the lack of specific drugs, several potential treatments were used for patients. This systematic review and meta-analysis will evaluate studies of the effects of favipiravir in COVID-19 pneumonia.
We will search electronic databases including LitCovid hub, PubMed, Scopus, ISI Web of Sciences, Cochrane and Embase using keywords related to COVID-19 and favipiravir. We will search the reference lists of all included studies and reviews. We will also search for clinical trial registries, such as ClinicalTrials.gov, for the ongoing clinical trials. All randomised clinical trials investigating the safety and efficacy of favipiravir compared with other control groups for the treatment of patients with confirmed infection with SARS-CoV-2 will be included. Patients' survival at the end of the treatment as well as the follow-up will be the primary outcome of the treatment, followed by the time and rate of the patient with a negative COVID-19 test. The desired secondary outcome will consist of a decreased rate of symptoms, proportion of intensive care unit (ICU) transfers, length of the hospital stay, ICU treatments, the quality of life and additional adverse events. Data synthesis will be conducted using CMA V.2. Two independent investigators will be screening titles, abstracts and full texts of included studies, based on eligibility criteria. These investigators will then independently extract the data and appraise the quality of said studies. All potential discrepancies will be resolved through consultation with the third reviewer. Statistical heterogeneity will be assessed using a standard I test. A funnel plot, Egger's test and Begg's test will be used for detecting asymmetry to explore possible publication bias.
All findings of this systematic review and meta-analysis will help identify the safety and efficacy of favipiravir for patients with COVID-19. Given that the design of the study is a systematic review, there is no need to follow the code of ethics protocol. The results of this study will be published in a reputable journal.
CRD42020180032.
2019 年 12 月中旬，中国武汉报告了严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的爆发，并于 2020 年 3 月 11 日被世界卫生组织宣布为大流行。由于该疾病的性质未知且缺乏特效药物，因此对多种潜在治疗方法进行了研究。本系统评价和荟萃分析将评估使用法匹拉韦治疗 COVID-19 肺炎的研究。
我们将使用与 COVID-19 和法匹拉韦相关的关键词，在包括 LitCovid hub、PubMed、Scopus、ISI Web of Sciences、Cochrane 和 Embase 在内的电子数据库中进行搜索。我们将搜索所有纳入研究和综述的参考文献列表。我们还将搜索临床试验注册处，如 ClinicalTrials.gov，以查找正在进行的临床试验。所有随机临床试验，只要研究了法匹拉韦与其他对照组相比，在治疗确诊感染 SARS-CoV-2 的患者方面的安全性和有效性，都将被纳入。患者治疗结束时的生存情况以及随访情况将是治疗的主要结局，其次是 COVID-19 检测呈阴性的患者的时间和比例。期望的次要结局将包括症状减轻率、转入重症监护病房（ICU）的比例、住院时间、ICU 治疗、生活质量和其他不良事件。使用 CMA V.2 进行数据综合。两名独立的调查员将根据纳入标准筛选标题、摘要和全文。然后，这些调查员将独立提取数据并评估研究的质量。所有潜在差异将通过与第三名评审员协商解决。将使用标准 I 检验评估统计异质性。将使用漏斗图、Egger 检验和 Begg 检验来检测不对称性，以探索可能的发表偏倚。
本系统评价和荟萃分析的所有发现都将有助于确定法匹拉韦治疗 COVID-19 患者的安全性和有效性。鉴于该研究的设计是系统评价，因此无需遵循伦理协议。本研究的结果将发表在著名期刊上。
PROSPERO 注册号：CRD42020180032。
